SecBot SecBot

ELVN

Enliven Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001672619 Biotech & Drug Discovery
$41.49 −0.03 (−0.07%)
Oct 26 4:00 PM ET · prev $41.52
Market cap
$3.1B
Mid cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$74.00
+78% · range $69.00–82.00
Next earnings
Nov 18
in 23 days · EPS est. −$0.45
1 year
+93.9%
from $21.40 · Oct 27
30 days
−9.8%
from $46.01
52-week range
$15.14–61.15
−32% from high · low Jan 6
Avg volume 20D
1.48M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$52.3M
0 buyers · 6 sellers · since Jun 17
New fund stakes
5
Q2 2026 13F · 1 exit
Filing reports
18
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 0 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 7/8 ·Next Earnings date, Nov 18, 2026
Strongest NEUTRAL Two senior executives at Enliven Therapeutics (CMO and CFO) sold a combined $424K in open-market sales on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $52.3M.

  • InstitutionsBULLISH

    Q2 2026: 41 added (5 new), 9 trimmed or exited. Largest new: Vanguard Capital Management $130.4M, Adage Capital Partners Gp, L.L.C $55.0M.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.432 → −$0.452 over 90 days. 0 up, 2 down in 30 days.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
5
new positions
1
exit
$238.9M
in new stakes
FundMoveSharesValue
FMR LLCADD10,025,017$508.8M
Polar Capital Holdings PlcADD6,430,636$326.4M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED2,903,907$147.4M
VANGUARD CAPITAL MANAGEMENT LLCNEW2,569,002$130.4M
GEODE CAPITAL MANAGEMENT, LLCADD1,407,202$71.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW1,083,313$55.0M
Candriam S.C.A.ADD905,674$45.9M
BALYASNY ASSET MANAGEMENT L.P.ADD607,189$30.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 12 analysts

Price is below the lowest target. Median implies +78%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 2, 2026Morgan Stanley
INITIATE
INITIATEOverweight
Oct 1, 2026JP Morgan
INITIATE
INITIATEOverweight
Aug 18, 2026William Blair
INITIATE
INITIATEOutperform
Aug 18, 2026Barclays
INITIATE
INITIATEOverweight
Aug 18, 2026Mizuho
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$52.3M
sold · 6 insiders
DateInsiderTypeValue
Oct 19, 2026
Hohl Benjamin
CHIEF FINANCIAL OFFICER
SELL$231.5K
Oct 19, 2026
Hohl Benjamin
CHIEF FINANCIAL OFFICER
EXERCISE$89.4K
Oct 19, 2026
Collins Helen Louise
CHIEF MEDICAL OFFICER
SELL$192.3K
Oct 19, 2026
Collins Helen Louise
CHIEF MEDICAL OFFICER
EXERCISE$12.4K
Oct 14, 2026
BALL KRISTINE M
Director
AWARD23,394 sh
Oct 1, 2026
Garland J. Scott
Director
EXERCISE$201.1K
Oct 1, 2026
Garland J. Scott
Director
SELL$606.7K
Sep 17, 2026
Collins Helen Louise
CHIEF MEDICAL OFFICER
EXERCISE$12.4K

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.45
EPS estimate, this quarter
−5%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.45-$0.52–-$0.38-0.9%$0.00
Next Q-$0.57-$0.69–-$0.46+3.4%$0.00
Current FY-$1.91-$2.55–-$1.38-3.7%$0.00
Next FY-$2.32-$2.60–-$1.94+0.9%$5.0K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Two senior executives at Enliven Therapeutics (CMO and CFO) sold a combined $424K in open-market sales on October 19…
CLUSTER — Impact 3/10
Oct 19, 2026 SEC
Director Helen Collins filed a Form 144 notice of intent to sell 15,000 shares of Enliven Therapeutics (ELVN), with an…
144 — Impact 2/10
Oct 19, 2026 Insider
Hohl Benjamin sold 6,018 shares
CHIEF FINANCIAL OFFICER @ $38.48 ($231.5K)
Oct 19, 2026 Insider
Hohl Benjamin acquired via exercise 6,018 shares
CHIEF FINANCIAL OFFICER @ $14.85 ($89.4K)
Oct 19, 2026 Insider
Collins Helen Louise sold 5,000 shares
CHIEF MEDICAL OFFICER @ $38.47 ($192.3K)
Oct 16, 2026 SEC
Kristine Ball filed a Form 3 initial statement of beneficial ownership with Enliven Therapeutics, Inc. (ELVN) after…
3 — Impact 2/10
Sep 30, 2026 Short interest report
Short Interest: ELVN up 20% to 10.4M shares
Settlement 2026-09-30 | Days to cover: 5.49 | ≈14.13% of shares outstanding (est.)
Jun 30, 2026 Inst.
FMR LLC — ADD
10,025,017 shares ($508.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
ELVN Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Sep 30, 2026
Short interest
Short Interest: ELVN up 20% to 10.4M shares
Settlement 2026-09-30 | Days to cover: 5.49 | ≈14.13% of shares outstanding (est.)
Sep 3, 2026
Press release
Enliven Therapeutics to Present at Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage…
Aug 31, 2026
Company news
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage…
Jun 30, 2026
Short interest
Short Interest: ELVN up 57% to 8.5M shares
Settlement 2026-06-30 | Days to cover: 3.09 | ≈14.00% of shares outstanding (est.)
Apr 6, 2026
Short interest
FTD: ELVN — 15,603 shares ($0.6M) failed to deliver
Settlement: 20260406, Price: $38.83, FTD Value: $605,864.49, ENLIVEN THERAPEUTICS INC COM

SecBot reports

18 filings · 2 bullish · 3 bearish · 13 neutral
All ELVN filing & press-release reports (18)